BULEVIRTIDE (Hepcludex ®)

Clinical Indication

Chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDV-RNA positive adult patients with compensated liver disease.

Date of classification

September 2022

Grey

Not yet reviewed drugs with no traffic light recommendation so not yet approved for use in LLR.

  • New medicines, devices, appliances.
  • New indication of existing medicine.
  • New NICE TA which has not been reviewed.
  • Not been requested for review by either TAS/LPT MMC.